Vše

Co hledáte?

Vše
Projekty
Výsledky výzkumu
Subjekty

Rychlé hledání

  • Projekty podpořené TA ČR
  • Významné projekty
  • Projekty s nejvyšší státní podporou
  • Aktuálně běžící projekty

Chytré vyhledávání

  • Takto najdu konkrétní +slovo
  • Takto z výsledků -slovo zcela vynechám
  • “Takto můžu najít celou frázi”

Midostaurin - the First Targeted Therapy Drug for Patients with Acute Myeloid Leukaemia with FLT3 Mutation

Identifikátory výsledku

  • Kód výsledku v IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F22%3A10465360" target="_blank" >RIV/00064165:_____/22:10465360 - isvavai.cz</a>

  • Nalezeny alternativní kódy

    RIV/00216208:11110/22:10465360

  • Výsledek na webu

    <a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=rvftc_dahW" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=rvftc_dahW</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.32383/appdr/159470" target="_blank" >10.32383/appdr/159470</a>

Alternativní jazyky

  • Jazyk výsledku

    angličtina

  • Název v původním jazyce

    Midostaurin - the First Targeted Therapy Drug for Patients with Acute Myeloid Leukaemia with FLT3 Mutation

  • Popis výsledku v původním jazyce

    The prognosis for patients with acute myeloid leukemia (AML) varies depending on genetic factors. The presence of mutations in the FMS-like tyrosine kinase 3 (FLT3) gene is found in approximately 30% of AML patients. Midostaurin, a first-generation multi-targeted tyrosine kinase inhibitor, is the first FLT3 inhibitor approved for the treatment of newly diagnosed AML patients with the FLT3 mutation in combination with standard induction and consolidation chemotherapy. However, as numerous clinical trials have shown, the list of indications for this drug is likely to be extended. Midostaurin can be administered orally, which improves the patient&apos;s comfort during treatment. In general, it has a favorable safety profile, but interactions with other drugs, such as strong CYP3A4 inhibitors or inducers, which are often used in the concomitant therapy of AML patients, may lead to changes in midostaurin plasma concentrations. In consequence, such interactions may increase the toxicity of the treatment or reduce its therapeutic effect. This review aims to summarise the current knowledge on midostaurin, i.e. its mechanisms of action, dosage, adverse effects, mechanisms of resistance, and limitations to its use. Due to the growing importance of the management of drug-drug interactions mediated via cytochrome CYP3A4, the main focus of this study is the pharmacokinetics of midostaurin and the variability of its plasma concentrations. The authors emphasize therapeutic drug monitoring with midostaurin as a potential method of managing AML patients with FLT3 mutation.

  • Název v anglickém jazyce

    Midostaurin - the First Targeted Therapy Drug for Patients with Acute Myeloid Leukaemia with FLT3 Mutation

  • Popis výsledku anglicky

    The prognosis for patients with acute myeloid leukemia (AML) varies depending on genetic factors. The presence of mutations in the FMS-like tyrosine kinase 3 (FLT3) gene is found in approximately 30% of AML patients. Midostaurin, a first-generation multi-targeted tyrosine kinase inhibitor, is the first FLT3 inhibitor approved for the treatment of newly diagnosed AML patients with the FLT3 mutation in combination with standard induction and consolidation chemotherapy. However, as numerous clinical trials have shown, the list of indications for this drug is likely to be extended. Midostaurin can be administered orally, which improves the patient&apos;s comfort during treatment. In general, it has a favorable safety profile, but interactions with other drugs, such as strong CYP3A4 inhibitors or inducers, which are often used in the concomitant therapy of AML patients, may lead to changes in midostaurin plasma concentrations. In consequence, such interactions may increase the toxicity of the treatment or reduce its therapeutic effect. This review aims to summarise the current knowledge on midostaurin, i.e. its mechanisms of action, dosage, adverse effects, mechanisms of resistance, and limitations to its use. Due to the growing importance of the management of drug-drug interactions mediated via cytochrome CYP3A4, the main focus of this study is the pharmacokinetics of midostaurin and the variability of its plasma concentrations. The authors emphasize therapeutic drug monitoring with midostaurin as a potential method of managing AML patients with FLT3 mutation.

Klasifikace

  • Druh

    J<sub>imp</sub> - Článek v periodiku v databázi Web of Science

  • CEP obor

  • OECD FORD obor

    30104 - Pharmacology and pharmacy

Návaznosti výsledku

  • Projekt

  • Návaznosti

    V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Ostatní

  • Rok uplatnění

    2022

  • Kód důvěrnosti údajů

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Údaje specifické pro druh výsledku

  • Název periodika

    Acta Poloniae Pharmaceutica

  • ISSN

    0001-6837

  • e-ISSN

    2353-5288

  • Svazek periodika

    79

  • Číslo periodika v rámci svazku

    6

  • Stát vydavatele periodika

    PL - Polská republika

  • Počet stran výsledku

    8

  • Strana od-do

    777-784

  • Kód UT WoS článku

    000992684900001

  • EID výsledku v databázi Scopus

    2-s2.0-85151408093